| Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia. | |
| | |
MedLine Citation:
|
PMID: 12624492 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The cytogenetic responses during the first chronic phase of 11 patients with chronic myeloid leukaemia (CML) treated with all-trans retinoic acid (ATRA) + interferon (IFN) were compared with those of 9 other CML patients treated with IFN alone. Metaphase and interphase cytogenetics and a semi-quantitative polymerase chain reaction were used to evaluate the cytogenetic responses. Two of the 11 patients in the ATRA + IFN group were withdrawn, one of them because of IFN intolerance, and the other because of non-compliance. Of the 9 remaining ATRA + IFN-treated patients 6 exhibited major cytogenetic responses, 3 of which were complete. Of the 9 patients treated with IFN alone, only 2 showed major cytogenetic responses. No severe adverse effects were observed. The preliminary results suggest that the ATRA + IFN combination may be superior in achieving cytogenetic remission in the first chronic phase of CML. |
| | |
Authors:
|
Miklós Egyed; Balázs Kollár; György Rumi; Eva Keller; János Vass; Sándorné Fekete |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Acta haematologica Volume: 109 ISSN: 0001-5792 ISO Abbreviation: Acta Haematol. Publication Date: 2003 |
Date Detail:
|
Created Date: 2003-03-07 Completed Date: 2003-03-27 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0141053 Medline TA: Acta Haematol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 84-9 Citation Subset: IM |
Copyright Information:
|
Copyright 2003 S. Karger AG, Basel |
Affiliation:
|
Department of Internal Medicine, Kaposi Mór County Hospital, Kaposvár, Hungary. egyedmiklos@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Combined Chemotherapy Protocols / administration & dosage Cytogenetic Analysis* Female Humans Interferon Alfa-2a / administration & dosage, therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*, genetics* Male Middle Aged Recurrence Remission Induction* Tretinoin / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
302-79-4/Tretinoin; 76543-88-9/Interferon Alfa-2a |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ceramide 1-phosphate formation in neutrophils.
Next Document: Severe aplastic anemia with autoimmune thyroiditis showing no hematological response to intensive im...